Revance Therapeutics Inc (RVNC)
3.025
-0.14
(-4.27%)
USD |
NASDAQ |
May 17, 16:00
3.02
0.00 (0.00%)
After-Hours: 20:00
Revance Therapeutics Revenue (Quarterly): 51.94M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 51.94M |
| December 31, 2023 | 69.80M |
| September 30, 2023 | 56.78M |
| June 30, 2023 | 58.13M |
| March 31, 2023 | 45.77M |
| December 31, 2022 | 49.92M |
| September 30, 2022 | 29.02M |
| June 30, 2022 | 28.37M |
| March 31, 2022 | 25.26M |
| December 31, 2021 | 25.95M |
| September 30, 2021 | 19.74M |
| June 30, 2021 | 18.80M |
| March 31, 2021 | 13.30M |
| December 31, 2020 | 11.13M |
| September 30, 2020 | 3.835M |
| June 30, 2020 | 0.299M |
| March 31, 2020 | 0.058M |
| December 31, 2019 | 0.089M |
| September 30, 2019 | 0.046M |
| June 30, 2019 | |
| March 31, 2019 | 0.278M |
| December 31, 2018 | 0.487M |
| September 30, 2018 | 2.362M |
| Date | Value |
|---|---|
| June 30, 2018 | 0.686M |
| March 31, 2018 | 0.193M |
| December 31, 2017 | 0.037M |
| September 30, 2017 | 0.075M |
| June 30, 2017 | 0.075M |
| March 31, 2017 | 0.075M |
| December 31, 2016 | 0.075M |
| September 30, 2016 | 0.075M |
| June 30, 2016 | 0.075M |
| March 31, 2016 | 0.075M |
| December 31, 2015 | 0.075M |
| September 30, 2015 | 0.075M |
| June 30, 2015 | 0.075M |
| March 31, 2015 | 0.075M |
| December 31, 2014 | 0.075M |
| September 30, 2014 | 0.075M |
| June 30, 2014 | 0.075M |
| March 31, 2014 | 0.158M |
| December 31, 2013 | 0.309M |
| September 30, 2013 | 0.158M |
| June 30, 2013 | 0.075M |
| March 31, 2013 | 0.075M |
| December 31, 2012 | 0.117M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.046M
Minimum
Sep 2019
69.80M
Maximum
Dec 2023
26.75M
Average
25.26M
Median
Mar 2022
Revenue (Quarterly) Benchmarks
| AbbVie Inc | 12.31B |
| Eli Lilly and Co | 8.768B |
| Aquestive Therapeutics Inc | 12.05M |
| Humacyte Inc | -- |
| AN2 Therapeutics Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -53.15M |
| Total Expenses (Quarterly) | 98.76M |
| EPS Diluted (Quarterly) | -0.58 |
| Enterprise Value | 468.20M |
| Gross Profit Margin (Quarterly) | 71.29% |
| Profit Margin (Quarterly) | -102.3% |
| Earnings Yield | -120.5% |
| Normalized Earnings Yield | -90.60 |